NASDAQ · Financial Statements
Bellerophon Therapeutics, Inc. (BLPH) Financial Statements
$0.01
NASDAQ: BLPH
Market Cap $146791
Overview Financials Dividend Bellerophon Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $20.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2018 2019 2020 2021 2022 Revenue $0 $0 $0 $0 $0 Operating Profit $-28.0M $-17.0M $-26.0M $-20.0M $-22.0M Net Profit $3.0M $-13.0M $-25.0M $-18.0M $-20.0M EPS $0.65 $-2.95 $-3.17 $-1.87 $-2.08 Op Margin — — — — —
Balance Sheet (USD)
Metric 2018 2019 2020 2021 2022 Total Assets $18.0M $13.0M $50.0M $27.0M $8.0M Total Liabilities $15.0M $10.0M $12.0M $5.0M $5.0M Cash $17.0M $10.0M $48.0M $25.0M $7.0M Borrowings $0 $2.0M $2.0M $1.0M $0
Cash Flow (USD)
Metric 2018 2019 2020 2021 2022 Operating Cash Flow $-15.0M $-13.0M $-20.0M $-23.0M $-18.0M Investing Cash Flow $3.0M $0 $0 $0 $0 Financing Cash Flow $0 $0 $3.0M $0 $0 Net Cash Flow $-12.0M $-7.0M $38.0M $-23.0M $-18.0M Free Cash Flow $-15.0M $-13.0M $-20.0M $-23.0M $-18.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA 0.30 FCF Yield -12105.65% Quick Ratio 1.40 Interest Coverage -165.81 Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .